In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth quarter 2024 investor letter. A ...

It's one of many changes Bayer CEO Bill Anderson has made. Still, the company's stock price this year has struggled.

Bayer AG plans to push pause on some of its pharmaceutical dealmaking, focusing instead on reducing the high debt load the ...

Bayer's CEO overhauled his corporate budget system with 90-day cycles to try to reduce bureaucracy. Bill Anderson said the inspiration came from a "radical experiment" at Genentech to kill budgets.

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

Whether ahead of their time, truly bizarre, or just plain doomed, it’s certainly interesting to see companies go completely ...

Bayer acquires rights to Cytokinetics' heart drug in Japan Some Bayer investors say CEO Bill Anderson should speed up turnaround efforts, including boosting efficiency and drug development ...

Bill Anderson has shaken up Bayer employees’ day-to-day since taking charge in 2023. © 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site ...

The solid quarter is important for Bayer as it tries to rebuild under chief executive Bill Anderson, who was brought in to steady the ship after a torrid few years marked by patent losses ...

In May, Bayer’s new American CEO, Bill Anderson, laid out a two-pronged strategy of continuing to vigorously contest Roundup lawsuits in courts and to insist on its safety while working on a ...